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ORIGINAL RESEARCH
Abstract: Asthma is a chronic disease with both inflammatory and bronchoconstrictive
elements and often requires multiple medications. Most asthma regimens include medications
with different therapeutic modes of action and a number of different medication delivery
devices. To effectively participate in their asthma management, patients need to recognize
each of their medication types, understand their purpose, adhere to their treatment regimen,
and be proficient in using the required delivery devices. This study evaluated patient knowledge
of asthma pharmacotherapy and adherence. An interview study was undertaken in two rural
locations, in Australia, to elicit participants’ knowledge, use, and inhalation device technique.
Of participants, 75.9% used preventer medication and the remaining 24.1% used reliever
medication only. Of those using preventer medication, 82.5% could distinguish their preventer
from a range of asthma medicines. Metered dose inhalers (MDIs) were used by 80% of
participants; 23% used a Turbuhaler®; 24% used an Accuhaler®; and 5% used an MDI with a
spacer device. The study established poor medication knowledge, suboptimal device technique,
and disturbing levels of adherence with management recommendations. Asthma education
strategies need to be modified to engage patients with low asthma knowledge to achieve
improved patient outcomes. Further, strategies need to motivate patients to use preventer
medication during times when they feel well.
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Asthma in Australia
With two out of five Australians exhibiting symptoms consistent with asthma at some
stage in their lives, asthma is one of Australia’s major health problems and is associated
with significant morbidity, avoidable mortality, and impaired quality of life (Woolcock
et al 2002; Wilson 2003). As a result of the prevalence of asthma in the general
community, which is widely considered to be 20% in children and 7%–12% in adults
(Bauman 1999), it would be expected that about one in ten adults that enter a pharmacy
suffer from asthma.
Asthma is a disease that has both chronic and acute components and often requires
complex management. Most people with asthma are prescribed regimens that include
multiple medications with different actions and one or more different devices for the
delivery of medications (NAC 2002). The increasing prevalence of asthma in Australia
and worldwide (Pearce et al 2000; Barraclough et al 2002; Mannino et al 2002)
means that patient understanding and adherence to asthma management guidelines
is critically important (AIHW 2000).
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Asthma management, patient
knowledge, and therapy
Aspects of disease management that are important to asthma
include knowledge of the disease, its treatment, and the
effective use of different therapies. Healthcare providers play
a crucial role in empowering patients with the necessary
skills and knowledge to manage their asthma.
It is important however to remember that whilst the goal
of a healthcare professional might be clinical, such as
objective improvement in lung function parameters, patients
are focused on their self-perceived health status, which likely
includes their ability to participate without limitation in their
everyday life (Clark and Partridge 2002). If not managed
effectively, asthma is potentially a debilitating condition that
can cause a reduced quality of life in terms of physical,
social, and psychological aspects (AIHW 2000; Mathers
2000; Wilson 2003).
Increasing patients’ knowledge about their asthma
therapy is vital to asthma management (Walker and Edwards
1999), as people with asthma are likely to be using multiple
medications and delivery devices. Fitzclarence and Henry
(1990) asked participants to give examples of medications
that could be used to prevent and treat asthma attacks. They
demonstrated that 50% of people with asthma knew the
action of different medications with some demonstrating
an exceptional level of knowledge (Fitzclarence and Henry
1990).
Medication is generally delivered directly to the lung
by specialized devices. These devices require that the patient
learn an effective device technique to use their medication
(Wilson 2003). Studies that have examined device technique
have recognized that MDIs are difficult for patients to use
as they require coordination, breath hold ability, and patient
hand strength and dexterity (Rydman et al 1999; Anderson
2001). Further, inhaler technique has been established to
decline rapidly over time and reassessment at each supply
can be beneficial (Clark and Partridge 2002; Pain 2003;
Wilson 2003).
Asthma management adherence
Meichenbaum and Turk (1987) conceptualize adherence as
“active, voluntary, collaborative involvement of the patient
in a mutually acceptable course of behavior to produce a
desired preventative or therapeutic result”. Some consider
that the terms adherence and compliance are synonymous.
By adopting this definition, reasoned agreement with the
management plan on the part of the patient is implied. Whilst
asthma management plans incorporate a number of
recommended health behaviors, the role of medication is
paramount. Medication adherence has been defined as “the
amount of time a patient takes a given medication as
prescribed” (Jones et al 2003, p 94). Rates of nonadherence
with pharmacotherapy across all chronic disease states
including asthma is high, ranging from 40%–70% (Clark
and Partridge 2002; Sawyer 2002). Patients should be
educated about their drug therapy including how the drugs
act so that they can make logical decisions regarding their
treatment, since use of medicinal drugs is not founded on
medication knowledge alone but also on lay reasoning and
logic (Lumme and Sandt et al 2000). People with asthma
can lead a normal and healthy life, and one major step in
insuring this is the adherence to their management plan. A
significant challenge for healthcare professionals is
motivating patients to take preventive medication when
asymptomatic (Anarella et al 2004). The aim of this study
was to evaluate patient knowledge of asthma pharmaco-
therapy and adherence.
Methods
Recruitment
The study was undertaken in five pharmacies in two rural
locations in Australia. All individuals entering the
pharmacies were, after a brief introduction, asked if they
had asthma and if so, were then invited to participate in the
study. The questionnaire was administered by one of the
researchers (TF) during a one-on-one interview. Times of
recruitment were varied in an attempt to avoid any bias or
restriction of the sample in relation to their gender, age, or
employment status. The Charles Sturt University Ethics in
Human Research Committee granted approval for this
project.
Interview schedule
A structured interview was conducted using a questionnaire
designed to elicit information in the following areas: basic
sociodemographics, asthma medication and management
knowledge, adherence, and quality of life (see Table 1).
Questions were asked exactly as written and in the order
specified by the interview schedule. During the interview,
participants were asked to identify their medication, and
describe their treatment regimen and the mode of action
of “preventer” and “reliever” medications. A colored
medication chart was used as a prompt because many
patients cannot remember their medication names but areTherapeutics and Clinical Risk Management 2005:1(1) 35
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more likely to be able to identify them. Additionally
participants were asked about their asthma management
plan. Participants’ medication adherence and skills at using
medication devices were also assessed.
Participants’ responses were recorded as discrete values,
free format, or multi-option responses as appropriate. Free
responses to medication and asthma knowledge items were
scored, summed, and categorized into 3 levels: “poor”,
“basic”, and “clear”. Each participant was invited to
demonstrate their technique using a placebo for the
medication delivery device that they regularly used. Their
device technique was scored against a checklist and
categorized.
Another component of the survey involved the use of an
asthma-specific quality of life (QOL) evaluation (Marks
1992). This questionnaire encompasses three domains of
life: the physical, social, and psychological aspects. In the
original version of the questionnaire, the participants were
presented with a series of five options to best describe their
response to each statement: “none”, “mildly”, “moderately”,
“severely”, and “very severely”. However, in the develop-
ment of this study it was felt that there was a certain degree
of ambiguity between the terms “severely” and “very
severely”, and so only four options were used: “none”,
“mildly”, “moderately”, and “severely”. Other researchers
have previously made adjustments to the subscale structure
and scoring of the questionnaire prior to its application to
eliminate perceived overlap (Katz et al 2001).
Analysis
The analysis of the data was performed using Statistical
Packages for the Social Sciences (SPSS) version 10.0
(Norusis 1993). Once the data had been collected, the
information was coded and entered into a database, verified
for data entry errors, and corrected. Frequencies, means,
and standard deviations were examined for all of the
participant responses. Cross-tabulations were also used to
identify relationships between the study variables. Scores
were calculated for the QOL section.
Results
Sociodemographics
There were 83 participants in the study. The participation
rate was 92% of those individuals eligible. The mean age of
participants was 58.9 (± 17.7) years. Forty-five percent of
respondents were male and 55% were female. Smokers
accounted for 14.5% of the respondents, with an average of
17.5 cigarettes smoked per day. The mean number of
occasions of exercise per week was 2.8.
Medication knowledge
Preventer medication was used by 75.9% of participants;
the remaining 24.1% used reliever medication only to
manage their condition. Of those using reliever alone, 30%
used it more than 3–4 times per week.
Respondents to items concerning mode of action of
“preventer” and “reliever” medications number 80.7%.
Participants provided a response in their own words with
6.3% providing an incorrect response when defining
preventer medication and 7.8% unable to define reliever
medication (refer to Figure 1).
Of participants using preventer medication, 82.5% could
distinguish and correctly identify their preventer from the
range of asthma medications. As the depth of knowledge of
the mode of action of preventer medication increased
(“basic” 81%; “clear” 95.7%), so did the participants ability
to identify their preventer medication.
Medication adherence
Thirty-eight percent of patients used preventer medication
as prescribed and 11% never used it (refer to Figure 2).
Table 1 Questionnaire structure
Domain Information about the domain
Sociodemographics 6 items: age, gender, ethnic background,
marital status, education, smoking status
Health professionals 2 items: health professionals role in asthma
management
Medication knowledge 5 items: information about patients
understanding of medication types and
actions
Medication adherence 6 items: frequency of missed doses of
medication and reasons
Asthma action plan 2 items: knowledge and ownership
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Figure 1 Participants’ knowledge of mode of action of “preventer” and
“reliever” medication.Therapeutics and Clinical Risk Management 2005:1(1) 36
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Participants offered a number of reasons explaining their
nonadherence: the most common (57%) was forgetting to
take preventer medication, 10% were too busy, 10% were
concerned about side effects, and 9% don’t believe it is
effective. Other responses were offered only by individual
participants and were not endorsed by the participant sample.
Older patients adhered to their medication regimen more
closely than younger patients (refer to Figure 3).
Medication device technique
Sixty-six percent of participants used only one device whilst
33.7% used two different devices. MDIs were used by 80%
of participants; 23% used a Turbuhaler
®; 24% used an
Accuhaler
®; and 5% used an MDI with a spacer device.
Effectiveness of device usage is classified for each device
type in Table 2. Errors in device technique arose at almost
every stage of the process of MDI device actuation (refer to
Figure 4).
Quality of life
The average QOL score for the sample population was found
to be 1.99 (range 0.83–8.13). Males had a higher mean QOL
score (2.17) than females (1.84). There was a significant
negative correlation (Pearson’s r –0.352, p = 0.001) between
QOL score and adherence with preventer medication such
that as quality of life decreased adherence with preventer
medication increased.
Discussion and conclusion
Pharmacies are an ideal site for surveying people with
chronic diseases as most are managed by prescribed
medicines. Interview studies have been shown to produce
better completion rates than other types of questionnaires
and are a good method for administration of detailed or
complex surveys (Bailey 1982). Surveying at local
pharmacies may however, introduce bias by recruiting
people who are perhaps more concerned for their health
(Lupton and Najman 1995).
People with asthma are likely to be using multiple
medications required at different times during the course of
the disease; therefore, increasing patients’ knowledge about
their asthma therapy is vital to asthma management (Walker
and Edwards 1999). In this study, we identified relatively
high preventer use with 79% of participants prescribed this
medication. Participants could describe the actions of
preventer (83.8%) and reliever (92.2%) medication
appropriately. Although there is a paucity of research
addressing this issue, these results are comparable to
previous Australian research that identified that 90% of those
surveyed were able to distinguish their preventer and reliever
medications and when to use them (Anonymous 2000).
However, other research conducted in Trinidad more
recently (Pinto-Pereira et al 2002), established that only 53%
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Figure 3 Effect of participant age on adherence.
Table 2 Effectiveness of participants’ device technique
Rating MDI 
(% users) MDI Turbuhaler
® Accuhaler
® + spacer
Ineffective 39 11 15 25
Acceptable 27 52 10 0
Optimal 34 37 75 75
Abbreviation: MDI, metered dose inhalers.
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Figure 4 Observed errors with metered dose inhaler (MDI) technique.
Figure 2 Participant adherence with “preventer” medication regimen.
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of chest clinic patients could provide accurate reasons for
using preventer and reliever medications.
Of concern was the overuse of reliever medication which
occurred in 30% of those using reliever alone to manage
their asthma. If a patient is over reliant on this medication
they may develop tachyphylaxis and when they need
bronchodilating action their reliever will not be as effective.
Regular use of reliever medications alone has been
associated with a 2.6 increased risk of death or near death
(Hartzema 2000). Clearly, asthma management guidelines
would indicate the use of preventer medication in this group.
While it is often reported that patients have difficulty
communicating to health professionals the medications they
are currently taking, this study found that over 80% could
correctly identify their medications from a medication chart.
The use of visual prompting is a strong tool for some people
and can provide a quick way for helping people to remember
a particular item (Sargeant and Unkenstein 1998), and its
use in future research is encouraged.
Poor adherence by people with asthma is extensively
documented especially for preventer medications (Sawyer
2002). Of those prescribed preventer in this study, only 38%
were adherent to dose and dose frequency recommendations,
a further 41% were adherent to dose but 11% did not use
their preventer at all. These results are consistent with other
research where 38% of respondents used preventer
medication as prescribed by their doctor (Anarella et al
2004). As QOL decreased, adherence with preventer
medication increased and this may be attributable to
increased patient motivation.
The major reason for nonadherence identified in this
study was forgetfulness. This is not unique to this study
and has been documented by other researchers (Chambers
et al 1999; Chapman et al 2000). Further reasons included
concern about side effects and a feeling that there was no
need to take the medication when well. This study therefore
identified areas for improvement in asthma management,
which included education about the risk/benefit ratio of
preventers. Additional strategies to address poor adherence
have been identified in the literature and include reducing
the dose frequency, and choosing the same type of delivery
device for both preventer and reliever medications (Sawyer
2002).
Our study identified suboptimal MDI device technique
with the most frequently recorded errors related to the
required changes in ventilatory pattern and breath holding.
This is consistent with the literature (Pinto-Pereira et al 2002;
Slader et al 2002; Pain 2003). Dry powder devices are
generally considered to present fewer problems due to a
lesser requirement for patient coordination (Pain 2003).
However, research has established that patients tend to lack
confidence in this device because a visible aerosol is not
produced nor sensed on the pharynx. Despite the differences
in devices, the critical feature in dosing efficacy rests more
on patient skill than the features of the device itself (Reed
2004). Consistent with the literature, this study provided
evidence of the need for improved and ongoing device use
education (Slader et al 2002).
Our study demonstrated that substantial numbers of
people with asthma lack the necessary knowledge to
contribute effectively to their disease state management.
Strategies need to be developed to engage patients with low
asthma knowledge in asthma education programs to achieve
improved patient outcomes, including quality of life.
Further, strategies need to be tailored to motivate patients
to take preventer medication during times when they
feel well.
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